Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Other financing activities (2021 - 2024)

Guided Therapeutics' Other financing activities history spans 3 years, with the latest figure at $12000.0 for Q3 2024.

  • For Q3 2024, Other financing activities changed N/A year-over-year to $12000.0; the TTM value through Dec 2024 reached $12000.0, down 99.53%, while the annual FY2024 figure was $29000.0, N/A changed from the prior year.
  • Other financing activities for Q3 2024 was $12000.0 at Guided Therapeutics, down from $2.5 million in the prior quarter.
  • Across five years, Other financing activities topped out at $2.5 million in Q4 2022 and bottomed at $12000.0 in Q3 2024.
  • The 3-year median for Other financing activities is $38000.0 (2021), against an average of $525600.0.
  • The largest YoY upside for Other financing activities was 10225.0% in 2022 against a maximum downside of 100.0% in 2022.
  • A 3-year view of Other financing activities shows it stood at $24000.0 in 2021, then soared by 10225.0% to $2.5 million in 2022, then tumbled by 99.52% to $12000.0 in 2024.
  • Per Business Quant, the three most recent readings for GTHP's Other financing activities are $12000.0 (Q3 2024), $2.5 million (Q4 2022), and $76000.0 (Q3 2022).